ClinicalTrials.Veeva

Menu
North America Research Institute | NARI San Dimas, CA - Dr. Jamal logo

North America Research Institute | NARI San Dimas, CA - Dr. Jamal

Research site

Site insights

Top conditions

Top treatments

LNP023
Semaglutide
BI 690517
Ziltivekimab
Empagliflozin
MK-2060
Atrasentan
Finerenone
Lorundrostat

Parent organization

This site is a part of North America Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Molly Way

Verified by this site

Active trials

11 of 11 total trials

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesit...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...

Enrolling
Primary IgA Nephropathy
Drug: LNP023

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial....

Enrolling
Primary Membranous Nephropathy
Drug: SNP-ACTH (1-39) Gel
Drug: Rituximab

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling
Heart Failure
Drug: vicadrostat
Drug: Empagliflozin
Locations recently updated

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular d...

Active, not recruiting
Immunoglobulin A Nephropathy
Alport Syndrome
Drug: Atrasentan

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Active, not recruiting
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting
End-Stage Renal Disease
End-Stage Kidney Disease
Drug: MK-2060
Drug: Placebo

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a...

Active, not recruiting
IgA Nephropathy
Drug: Placebo
Drug: LNP023

Trial sponsors

Novartis logo
Novo Nordisk logo
Bayer logo
Boehringer Ingelheim logo
C
Merck Sharp & Dohme (MSD) logo
M
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems